Land: Europese Unie
Taal: Engels
Bron: EMA (European Medicines Agency)
pegfilgrastim
Pfizer Europe MA EEIG
L03AA13
pegfilgrastim
Immunostimulants,
Neutropenia
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Revision: 5
Authorised
2020-11-18
22 B. PACKAGE LEAFLET 23 PACKAGE LEAFLET: INFORMATION FOR THE USER NYVEPRIA 6 MG SOLUTION FOR INJECTION pegfilgrastim This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Nyvepria is and what it is used for 2. What you need to know before you use Nyvepria 3. How to use Nyvepria 4. Possible side effects 5. How to store Nyvepria 6. Contents of the pack and other information 1. WHAT NYVEPRIA IS AND WHAT IT IS USED FOR Nyvepria contains the active substance pegfilgrastim. It is used in patients treated with cytotoxic chemotherapy (medicines that destroy rapidly growing cells) to reduce the duration of neutropenia (low neutrophil count, a type of white blood cell) and to help prevent febrile neutropenia (low white blood cell count with a fever). Nyvepria is for use in adults aged 18 years and over. White blood cells are important for fighting off infection. If the white blood cell count to fall too low, due to your cytotoxic chemotherapy, your body may not be able to fight off microorganisms and this will increase the chances of an infection. Pegfilgrastim, is very similar to a natural protein in the body called granulocyte colony stimulating factor and it works by encouraging your bone marrow to produce more white blood cells that help your body fight off infe Lees het volledige document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Nyvepria 6 mg solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 6 mg of pegfilgrastim* in 0.6 mL solution for injection. The concentration is 10 mg/mL based on protein only**. *Produced in _Escherichia coli _cells by recombinant DNA technology followed by conjugation with polyethylene glycol (PEG). **The concentration is 20 mg/mL if the PEG moiety is included. The potency of this medicinal product should not be compared to the potency of another pegylated or non-pegylated protein of the same therapeutic class. For more information, see section 5.1. Excipients with known effect Each pre-filled syringe contains 30 mg sorbitol (E420) (see section 4.4). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless, free from visible particles, solution for injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Nyvepria therapy should be initiated and supervised by physicians experienced in oncology and/or haematology. Posology One 6 mg dose (a single pre-filled syringe) of Nyvepria is recommended for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy. 3 Special populations _Renal impairment_ No dose change is recommended in patients with renal impairment, including those with end-stage renal disease. _Paediatric population_ The safety and efficacy of pegfilgrastim in child Lees het volledige document